• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Present and future challanges in the treatment of haemophilia: a clinician's perspective.

作者信息

Mannucci Pier Mannuccio, Franchini Massimo

机构信息

Scientific Direction, IRCCS Ca' Granda Maggiore Policlinico Hospital Foundation, Milan, Italy.

Department of Transfusion Medicine and Haematology, Carlo Poma Hospital, Mantua, Italy.

出版信息

Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s77-81. doi: 10.2450/2013.012s.

DOI:10.2450/2013.012s
PMID:24333317
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3853988/
Abstract
摘要

相似文献

1
Present and future challanges in the treatment of haemophilia: a clinician's perspective.血友病治疗中的当前及未来挑战：临床医生视角
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s77-81. doi: 10.2450/2013.012s.
2
Present and future challenges in the treatment of haemophilia: the patient's perspective.血友病治疗中的当前与未来挑战：患者视角
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s82-5. doi: 10.2450/2013.013s.
3
Recent evolution of clotting factor concentrates for hemophilia A and B. Transfusion Practices Committee.用于甲型和乙型血友病的凝血因子浓缩剂的最新进展。输血实践委员会。
Transfusion. 1993 May;33(5):422-34. doi: 10.1046/j.1537-2995.1993.33593255605.x.
4
Development and introduction of recombinant factor VIII--a clinician's experience.重组凝血因子VIII的研发与应用——临床医生的经验
Haemophilia. 2012 Jul;18(4):483-6. doi: 10.1111/j.1365-2516.2012.02804.x. Epub 2012 Apr 19.
5
Health economics in haemophilia: a review from the clinician's perspective.血友病的卫生经济学：从临床医生的角度进行的综述。
Haemophilia. 2010 May;16 Suppl 3:29-34. doi: 10.1111/j.1365-2516.2010.02257.x.
6
Health economic models in hemophilia A and utility assumptions from a clinician's perspective.从临床医生角度看血友病A中的健康经济模型及效用假设
Pediatr Blood Cancer. 2015 Oct;62(10):1826-31. doi: 10.1002/pbc.25543. Epub 2015 May 14.
7
Advances and innovations in haemophilia treatment.血友病治疗的进展与创新。
Nat Rev Drug Discov. 2018 Jul;17(7):493-508. doi: 10.1038/nrd.2018.70. Epub 2018 Jun 8.
8
Prophylactic treatment of patients with haemophilia A or haemophilia B.对甲型血友病或乙型血友病患者进行预防性治疗。
Vox Sang. 2005 Jan;88(1):62-7. doi: 10.1111/j.1423-0410.2005.00588.x.
9
Switching haemophilia products and inhibitor risk: a United States' perspective.血友病产品转换与抑制物风险：美国视角
Eur J Haematol. 2015 Apr;94(4):283. doi: 10.1111/ejh.12441.
10
The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters.罗丁（血友病患者中抑制剂产生决定因素的研究）研究：血友病治疗者视角下的临床难题。
Haemophilia. 2013 May;19(3):351-4. doi: 10.1111/hae.12149. Epub 2013 Apr 12.

引用本文的文献

1
Development and validation of the Child Hemophilia Treatment Experience Measure: A new observer-reported outcome measure.儿童血友病治疗体验量表的开发与验证：一种新的观察者报告结局指标
Haemophilia. 2025 Jan;31(1):48-62. doi: 10.1111/hae.15102. Epub 2024 Oct 10.
2
Understanding treatment burden in hemophilia: development and validation of the Hemophilia Treatment Experience Measure (Hemo-TEM).理解血友病的治疗负担：血友病治疗体验量表（Hemo-TEM）的开发和验证。
J Patient Rep Outcomes. 2023 Feb 23;7(1):17. doi: 10.1186/s41687-023-00550-6.
3
Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review.血友病 A 患者过渡到成人期时的因子 VIII 替代预防治疗：系统文献回顾。
Orphanet J Rare Dis. 2021 Jun 26;16(1):287. doi: 10.1186/s13023-021-01919-w.
4
Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort.靶向抗凝血酶治疗 A 型或 B 型血友病的研究性 siRNA 治疗药物 fitusiran-1 期抑制剂队列研究结果。
J Thromb Haemost. 2021 Jun;19(6):1436-1446. doi: 10.1111/jth.15270. Epub 2021 May 18.
5
System performance evaluation of the cobas t 711 and cobas t 511 coagulation analyzers in routine laboratory settings.在常规实验室环境中对 cobas t 711 和 cobas t 511 凝血分析仪的系统性能评估。
Blood Coagul Fibrinolysis. 2020 Oct;31(7):459-468. doi: 10.1097/MBC.0000000000000947.
6
The Neonatal Fc Receptor (FcRn): A Misnomer?新生儿 Fc 受体（FcRn）：一个用词不当的名称？
Front Immunol. 2019 Jul 10;10:1540. doi: 10.3389/fimmu.2019.01540. eCollection 2019.
7
Emicizumab for the treatment of haemophilia A: a narrative review.依库珠单抗治疗 A 型血友病：一篇叙述性综述。
Blood Transfus. 2019 May;17(3):223-228. doi: 10.2450/2019.0026-19.
8
Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII.使用聚乙二醇化重组凝血因子VIII（N8-GP）治疗的甲型血友病患者的健康相关生活质量和治疗满意度：一种新型重组长效凝血因子VIII。
Patient Prefer Adherence. 2019 Apr 9;13:497-513. doi: 10.2147/PPA.S196103. eCollection 2019.
9
Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia.影响血友病凝血因子浓缩物质量、安全性和上市批准的因素。
Blood Transfus. 2018 Nov;16(6):525-534. doi: 10.2450/2018.0150-18. Epub 2018 Sep 3.
10
Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia.IgG Fc 段的免疫耐受特性及其与血友病治疗和管理的相关性。
Blood. 2018 May 17;131(20):2205-2214. doi: 10.1182/blood-2017-12-822908. Epub 2018 Mar 27.

本文引用的文献

1
Future of coagulation factor replacement therapy.凝血因子替代治疗的未来。
J Thromb Haemost. 2013 Jun;11 Suppl 1:84-98. doi: 10.1111/jth.12270.
2
The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters.罗丁（血友病患者中抑制剂产生决定因素的研究）研究：血友病治疗者视角下的临床难题。
Haemophilia. 2013 May;19(3):351-4. doi: 10.1111/hae.12149. Epub 2013 Apr 12.
3
Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A.增强重组因子 VIII 的药代动力学特性：在血友病 A 患者中进行的糖基化 PEG 化重组因子 VIII 的首次人体试验。
J Thromb Haemost. 2013 Apr;11(4):670-8. doi: 10.1111/jth.12161.
4
Factor VIII products and inhibitor development in severe hemophilia A.VIII 因子产品与严重甲型血友病抑制物的产生。
N Engl J Med. 2013 Jan 17;368(3):231-9. doi: 10.1056/NEJMoa1208024.
5
Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.新型凝血因子 IX 与白蛋白融合蛋白（rIX-FP）在乙型血友病患者中的安全性和药代动力学。
Blood. 2012 Sep 20;120(12):2405-11. doi: 10.1182/blood-2012-05-429688. Epub 2012 Aug 2.
6
The modern treatment of haemophilia: a narrative review.血友病的现代治疗：一篇叙述性综述。
Blood Transfus. 2013 Apr;11(2):178-82. doi: 10.2450/2012.0166-11. Epub 2012 Jul 4.
7
Past, present and future of hemophilia: a narrative review.血友病的过去、现在和未来：叙事性综述。
Orphanet J Rare Dis. 2012 May 2;7:24. doi: 10.1186/1750-1172-7-24.
8
Modern haemophilia care.现代血友病护理。
Lancet. 2012 Apr 14;379(9824):1447-56. doi: 10.1016/S0140-6736(11)61139-2. Epub 2012 Mar 27.
9
How we choose factor VIII to treat hemophilia.我们如何选择因子 VIII 治疗血友病。
Blood. 2012 May 3;119(18):4108-14. doi: 10.1182/blood-2012-01-394411. Epub 2012 Mar 12.
10
The hope and reality of long-acting hemophilia products.长效血友病产品的希望与现实。
Am J Hematol. 2012 May;87 Suppl 1:S33-9. doi: 10.1002/ajh.23146. Epub 2012 Mar 3.